https://orcid.org/0000-0002-9844-2813
References
- Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19–27.
- Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358(13):1362–1369.
- Wahl S, Quirolo KC. Current issues in blood transfusion for sickle cell disease. Curr Opin Pediatr. 2009;21(1):15–21.
- Delicou S, Lavda M, Argiri V, et al. Combination of exchange transfusion treatment and hydroxyurea cause beneficial changes to laboratory parameters and clinical outcome in patients with sickle cell disease/β thalassemia compared with hydroxyurea or exchange transfusion alone. Hematol Transfus Int J. 2016;2(4):71–75.
- Koskinas J, Manesis EK, Zacharakis GH, et al. Liver involvement in acute vaso-occlusive crisis of sickle cell disease: prevalence and predisposing factors. Scand J Gastroenterol. 2007;42(4):499–507.
- Ladis V, Drossou M, Vini D, et al. Deferasirox safety profile in patients with transfusion-dependent anaemias: results from the interim analysis of a Hellenic study. E-poster presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA, USA, December 10–13 2011. Blood. 2011;118(21):3183–3183.
- Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54(4):650–659.
- Gandon Y, Olivié D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363(9406):357–362.
- de Araujo OM, Ivo ML, Ferreira Júnior MA, et al. Survival and mortality among users and non-users of hydroxyurea with sickle cell disease. Rev Lat Am Enfermagem. 2015;23(1):67–73.
- Ballas SK, Barton FB, Waclawiw MA, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. [in English, Portuguese and Spanish]. Health Qual Life Outcomes. 2006;4:59.
- Italia KY, Jijina FJ, Merchant R, et al. Response to hydroxyurea in beta-thalassemia major and intermedia: experience in western India. Clin Chim Acta. 2009;407(1–2):10–15.
- Alebouyeh M, Moussavi F, Haddad-Deylami H, et al. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening. Ann Hematol. 2004;83(7):430–433.
- Zamani F, Shakeri R, Eslami SM, et al. Hydroxyurea therapy in 49 patients with major beta-thalassemia. Arch Iran Med. 2009;12(3):295–297.
- Kayyali R, Pannala AS, Khodr H, et al. Comparative radical scavenging ability of bidentate iron (III) chelators. Biochem Pharmacol. 1998;55(8):1327–1332.
- Bertrand S, Hélesbeux JJ, Larcher G, et al. Hydroxamate, a key pharmacophore exhibiting a wide range of biological activities. Mini Rev Med Chem. 2013;13(9):1311–1326.
- Italia K, Colah R, Ghosh K. Hydroxyurea could be a good clinically relevant iron chelator. PLoS One. 2013;8(12):e82928.
- Italia K, Jain D, Gattani S, et al. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis. 2009;42(1):25–31.
- Maggio A, Rigano P, D’Amico G, et al. Treatment with hydroxyurea and iron chelation therapy in patients with hemoglobinopathies. Eur J Haematol. 2005;75(3):267–269.
- Al-Khateeb RS, Althagafy HS, ElAssouli MZ, et al. Iron chelation reduces DNA damage in sickle cell anemia. Clin Appl Thromb Hemost. 2021;27:10760296211047230.